Updated: Dec 29, 2022
Welcome to Cannabinoid Clinic, an education project powered by Higher Learning LV. This series provides cannabis and hemp industry professionals with easily digested cannabinoid profiles that ask little of your time—but provide plenty of science-based information.
There are two categories of cannabinoids: Phytocannabinoids and endocannabinoids. Phytocannabinoids are those produced by cannabis/marijuana/hemp, while endocannabinoids are made by the human body. This series covers both.
CBGV molecular structure
What is CBGV?
Cannabigerovarin (CBGV), a minor cannabinoid, is the varin version of cannabigerol (CBG). It results from CBGVA, the "meta" acidic precursor in cannabis that also morphs into CBDVA (which results in cannabidivarin, or CBDV) and THCVA (producing tetrahydrocannabivarin, or THCV). Under the right environmental conditions, CBGV may morph into cannabidiol (CBD).
"The scant research that is available for CBGV indicates that it may play a role in treating cancer, dry skin, and pain."
The scant research that is available for CBGV indicates that it may play a role in treating cancer, dry skin, and pain. More studies are needed to clarify the biochemical role of CBGV, with a focus on clinical trials involving human subjects.
CBGV Fast Facts
Role: Results from CBGVA
Biosynthetic pathway: CBGVA > CBGV > CBD
Acidic precursor: CBGVA
Boiling point: 834° F
Primary medical benefits: Cancer, pain, epilepsy, dry skin
CBGV Medicinal Benefits
Like many minor cannabinoids, much less research has been conducted on CBGV than major cannabinoids such as CBD and tetrahydrocannabinol (THC). The few studies that have been conducted have revealed that CBGV may be a good treatment for dry skin, cancer, and pain relief. It may also help glaucoma and epilepsy.
A December 2010 study entitled "Effects of Cannabinoids and Cannabinoid-enriched Cannabis Extracts on TRP Channels and Endocannabinoid Metabolic Enzymes" that was published in the British Journal of Pharmacology explored "the effects of 11 pure cannabinoids and botanical extracts from Cannabis varieties."
CBGV and related cannabinoids may provide "analgesic, anti-inflammatory, and anti-cancer qualities."
This study found that CBGV stimulated a particular cellular receptor in the endocannabinoid system (ECS), TRPV1. Based on its interaction with this and other ECS receptors, the researchers concluded that CBGV and related cannabinoids may provide "analgesic, anti-inflammatory, and anti-cancer" qualities.
An October 2013 study entitled "Enhancing the Activity of Cannabidiol and Other Cannabinoids In Vitro Through Modifications to Drug Combinations and Treatment Schedules" that was published in the journal Anticancer Research explored "the activity of six cannabinoids, used both alone and in combination, in leukaemic cancer cells," including CBGV.
The study revealed that the six cannabinoids reduced the number of cancer cells via a "cytostatic" effect that killed them, meaning that these molecules inhibited or suppressed the cellular growth of the cancer cells. The scientists concluded that their data "suggest a simultaneous arrest in [cancer] cell progression at all phases of the cell cycle" resulting from treatment with CBGV and the other five cannabinoids.
An April 2016 study entitled "Differential Effectiveness of Selected Non-psychotropic Phytocannabinoids on Human Sebocyte Functions Implicates Their Introduction in Dry/Seborrhoeic Skin and Acne Treatment" that was published in the journal Experimental Dermatology explored the "anti-acne effects of...non-psychotropic phytocannabinoids," including cannabichromene (CBC), CBDV, cannabigerol (CBG), CBGV, and (THCV). (THCV).
Reported the study: "We have previously shown that a non-psychotropic phytocannabinoid CBD exerted complex anti-acne effects by...reducing proliferation and alleviating inflammation in human sebocytes." It found that low doses (up to 10 μm) of the cannabinoids "only negligibly altered the viability of the sebocytes," but that stronger doses (≥50 μm) induced apoptosis" (cell death).
The scientists reported that their research reveals that "CBG and CBGV may have potential in the treatment of dry-skin syndrome, whereas CBC, CBDV, and especially THCV show promise to become highly efficient, novel anti-acne agents." Thus, this study revealed that CBGV and CBG may be better at alleviating dry skin and conditions involving dry skin, whereas other cannabinoids, including CBDV and THCV, are more effective for treatment of acne.
The study's authors dubbed the anti-inflammatory qualities of these cannabinoids "remarkable," stating that they show great promise as "efficient, yet safe novel tools in the management of cutaneous inflammations."
How to Get CBGV
Like other minor cannabinoids, cannabis cultivars and products featuring efficacious volumes of CBGV are few and far between. In loose-leaf marijuana flower, cultivars featuring larger amounts of CBG are more likely to feature more CBGV.
"In loose-leaf marijuana flower, cultivars featuring larger amounts of CBG are more likely to feature more CBGV."
Some companies are beginning to introduce products featuring varin cannabinoids, including CBDV, THCV, and CBGV. As such products become available, they will appear in the form of edibles (typically gummies), 510 vape cartridges, and sublingual tinctures.
🎧 Like what you just read? Listen and learn with our highly educational weekly Cannabis Commerce + Chemistry Podcast. At under 30 minutes per episode, it helps industry professionals stay current on trending topics.